Published On : September 2026
A buyer comparing Gamma Knife platforms purely by generation, the Icon versus an earlier installed platform, is skipping the constraint that actually narrows the field first.
Within the Leksell Gamma Knife market, patient volume category is the investment decision made first, since whether a centre operates at high, mid or emerging patient volume shapes whether it can justify a newer Icon platform and associated software investment, or instead operates an earlier installed platform through a service and upgrade path.
This page describes five product type categories and three patient volume categories strictly as market segments.
It provides no clinical, diagnostic or treatment guidance, and makes no claim about treatment efficacy or clinical outcome for any platform.
A high-volume radiosurgery centre treating a broad range of intracranial indications will generally justify continuous software and treatment planning investment, regardless of which specific platform generation it currently operates.
That is why hospital administrators experienced in this market lead capital planning conversations with patient volume category rather than with a preferred platform generation alone.
Five product type categories complete the specification once patient volume category is established, spanning the Leksell Gamma Knife Icon, earlier installed platforms, software and treatment planning solutions, service and maintenance programmes, and upgrades and modernisation services.
Software and treatment planning solutions and service and maintenance programmes together represent the categories most consistently purchased across all three patient volume tiers, reflecting their position as an ongoing operating requirement rather than a one-time acquisition.
Upgrades and modernisation services are generally paired with centres operating earlier installed platforms, reflecting the more incremental investment path these centres typically follow relative to a full platform replacement.
For buyers, establishing patient volume category for the specific programme involved is the starting point for any Gamma Knife platform investment conversation.
For manufacturers, product range breadth across all five categories widens the addressable share of any centre's investment stage, from initial acquisition through ongoing software and service relationships.
This pattern holds across every one of this report's five product type categories, since a platform investment decision made for a high-volume centre generally cannot simply be applied to an emerging programme without a fresh capital planning review.
For a hospital system managing multiple radiosurgery programmes across different patient volume tiers, a single manufacturer relationship rarely covers the full range of investment needs without a broad service and software portfolio behind it.
The Leksell Gamma Knife Icon is Elekta's current-generation platform and the newest product type category tracked in this report.
It is named here as a market category, and this page states nothing about how the platform functions or what treatment outcome it achieves.
The Icon platform and software and treatment planning solutions together account for the largest product type category by revenue identified in this report.
The Icon platform is generally specified by centres pursuing new installed base or full platform replacement, distinct from the incremental upgrade and modernisation path more common among centres operating earlier installed platforms.
This category draws interest from academic medical centres and cancer hospitals in particular, given the platform's position as Elekta's current generation offering.
For buyers, an Icon platform acquisition is typically evaluated alongside the software and treatment planning solutions and service and maintenance programmes a centre will also require over the platform's operating life.
For manufacturers, the Icon platform category anchors ongoing software and service relationships that extend well beyond the initial acquisition itself.
Commercially, an Icon platform acquisition typically carries a materially higher initial capital outlay than an incremental upgrade to an earlier installed platform, reflecting the difference between a full platform replacement and an incremental modernisation path.
This cost positioning is a factor buyers weigh alongside patient volume category, particularly for programmes considering whether to pursue full replacement or a staged upgrade path instead.
For buyers, requesting a manufacturer's software and treatment planning roadmap alongside any Icon platform proposal is a reasonable step given how closely the two categories are tied together commercially.
Earlier installed Gamma Knife platforms represent a substantial share of the more than 360-unit global installed base and remain in active clinical use across a wide range of centres.
This category is described here strictly as a market segment, and this page makes no claim about the clinical performance of any platform generation relative to another.
Earlier installed platforms are generally paired with service and maintenance programmes and upgrades and modernisation services, reflecting the more incremental investment path many centres operating them tend to follow.
Mid-volume specialty centres and emerging radiosurgery programmes account for a comparatively larger share of earlier installed platform operation than high-volume centres, which more frequently pursue Icon platform replacement.
For buyers operating an earlier installed platform, a manufacturer's upgrade and modernisation roadmap is often as commercially relevant as any new platform proposal.
For manufacturers, the earlier installed platform base represents an ongoing service, software and upgrade revenue opportunity independent of new platform sales.
This installed base also shapes replacement timing decisions, since a centre's decision to pursue a full Icon platform replacement rather than continued upgrades is typically driven by patient volume growth and referral base expansion rather than platform age alone.
Software and treatment planning solutions form a product type category purchased across all three patient volume tiers tracked in this report, distinct from the platform hardware categories addressed elsewhere on this page.
This category is described here strictly as a market category, and this page makes no claim about treatment planning accuracy or clinical outcome.
Software and treatment planning solutions are generally licensed and upgraded on a separate commercial cycle from the underlying platform hardware, reflecting their position as an ongoing capability investment rather than a one-time acquisition.
High-volume radiosurgery centres and mid-volume specialty centres account for the more consistent software and treatment planning investment activity identified in this report, tied to their broader range of treatment indications addressed.
For buyers, software and treatment planning capability is increasingly evaluated as a distinct line item from platform hardware during procurement, rather than bundled implicitly into a single acquisition decision.
For manufacturers, software and treatment planning solutions represent a recurring revenue category that extends a platform relationship well beyond its initial hardware acquisition.
|
TECHNOLOGY WATCH Software and treatment planning solutions are increasingly procured and upgraded on a separate commercial cycle from platform hardware, a shift that is extending manufacturer relationships with high-volume and mid-volume centres well past the original hardware acquisition. |
Service and maintenance programmes and upgrades and modernisation services together form the categories most closely tied to the age and configuration of a centre's existing installed platform.
This page states nothing about how any service, maintenance, upgrade or modernisation activity is technically performed.
Service and maintenance programmes are purchased across all three patient volume tiers, while upgrades and modernisation services are more concentrated among centres operating earlier installed platforms.
The clinical workflow model a centre operates also shapes how service and upgrade decisions are prioritised, since a multidisciplinary brain tumour centre addressing a broader range of gamma knife treatment indications typically maintains a more continuous service and upgrade cadence than a standalone radiosurgery programme.
For buyers, service and maintenance programme terms are frequently negotiated alongside any upgrade or modernisation proposal rather than treated as a separate procurement exercise.
For manufacturers, this grouping represents the most durable revenue relationship with any centre, extending well beyond the platform's original acquisition.
High-volume radiosurgery centres, mid-volume specialty centres and emerging radiosurgery programmes together define the patient volume category dimension tracked in this report.
High-volume radiosurgery centres account for the largest patient volume category by revenue identified in this report, and emerging radiosurgery programmes form the fastest-growing patient volume category as new markets establish initial installed base.
Mid-volume specialty centres occupy a position between these two categories, typically operating a mix of Icon platform and earlier installed platform investment depending on programme maturity.
The gamma knife equipment manufacturers covered in this report differ in how they approach each patient volume tier, with some concentrating commercial effort on high-volume centre replacement cycles and others prioritising emerging programme establishment.
For buyers, understanding which patient volume category a programme currently occupies, and which it is likely to grow into, is a more useful planning exercise than evaluating platform generation in isolation.
For manufacturers, patient volume category segmentation shapes which commercial approach, direct platform sales, software and service relationships, or emerging programme establishment support, is most relevant to a given buyer conversation.
The Leksell Gamma Knife Icon, earlier installed platforms, software and treatment planning solutions, service and maintenance programmes, and upgrades and modernisation services, framed strictly as market categories.
Elekta's current-generation Gamma Knife platform, named here as a market category. This page makes no claim about how the platform functions or what treatment outcome it achieves.
Earlier installed platforms remain in active clinical use across a large share of the global installed base and are generally paired with service and upgrade programmes, while the Icon is Elekta's current-generation platform more often specified for new installed base or full replacement.
This report describes service and maintenance programmes strictly as a market category purchased across all three patient volume tiers, without describing how any service or maintenance activity is technically performed.
Patient volume category shapes whether a centre can justify a newer Icon platform and associated software investment or instead operates an earlier installed platform through a service and upgrade path.